Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan’s prototypical chemical structure. The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan. It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism. It is grouped under the following drug class(es): Angiotensin II Receptor Blockers (ARBs). Its therapeutic use is listed as antihypertensives. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include saprisartanum and 3-[[3-bromo-2-[2-(trifluoromethylsulfonylamino)phenyl]-1-benzofuran-5-yl]methyl]-5-cyclopropyl-2-ethylimidazole-4-carboxamide. Its PubChem CID is 60921.
Saprisartan
| CAS No | 146623-69-0 |
|---|---|
| Molecular Formula | C25H22BrF3N4O4S |
| Molecular Weight | 611.4 g/mol |
| Synonyms | 3-[[3-bromo-2-[2-(trifluoromethylsulfonylamino)phenyl]-1-benzofuran-5-yl]methyl]-5-cyclopropyl-2-ethylimidazole-4-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan.
The listed CAS number is 146623-69-0.
The listed molecular formula is C25H22BrF3N4O4S.
The listed molecular weight is 611.4 g/mol.
3-[[3-bromo-2-[2-(trifluoromethylsulfonylamino)phenyl]-1-benzofuran-5-yl]methyl]-5-cyclopropyl-2-ethylimidazole-4-carboxamide.
The source lists saprisartanum and 3-[[3-bromo-2-[2-(trifluoromethylsulfonylamino)phenyl]-1-benzofuran-5-yl]methyl]-5-cyclopropyl-2-ethylimidazole-4-carboxamide.